Vital Biopharmaceutical Insights and Analytics

for Experts from Experts

Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.

Learn More

Cognitive Impairment Associated with Schizophrenia: What Clinical Attributes Will Be Most Persuasive for Psychiatrists and Payers Regarding the First Novel Drugs in this Highly Underserved Arena?

Surveyed U.S. psychiatrists would prescribe EnVivo Pharmaceuticals/Bayer HealthCare/Mitsubishi Tanabe Pharma’s encenicline to 25 percent of their patients with cognitive impairment associated with schizophrenia ... Learn More

Multiple Sclerosis in the EU5: How are physicians and payers responding to Aubagio, Lemtrada and Tecfidera?

Join us live on May 15, 2014... Learn More

View Webinar schedule and archive

Search Reports


See which reports have been searched on the most.


In the Spotlight

Join us in San Francisco

Come join us for an exciting one-day seminar.
Walk away with expert insights on ACOs,
Exchanges and the impact of Healthcare Reform.

View the Agenda  |  Meet our expert speakers

Recent Reports [ view all ]

  • Asthma (Moderate to Severe)

    Although several effective anti-inflammatory agents and bronchodilators are currently available for controlling disease... Read More

  • Chronic Obstructive Pulmonary Disease

    Treatment of chronic obstructive pulmonary disease (COPD) is dominated by bronchodilators, and polypharmacy is... Read More

  • Psoriatic Arthritis

    The availability of tumor necrosis factor alpha (TNF-a) inhibitors as therapeutic options has revolutionized the... Read More

Decision Resources Group brands include: